Plus Therapeutics regains Nasdaq compliance after 1-for-25 reverse stock split

Filed April 21, 2026 · Period ending April 20, 2026 · ~1 min read

Key Changes

• high

  Nasdaq notified the company on April 20 that it has regained compliance with the minimum $1.00 bid price requirement, avoiding delisting from the Nasdaq Capital Market.

  Item 8.01 verify on EDGAR →
• high

  The compliance was achieved through a 1-for-25 reverse stock split effective April 2, 2026, which consolidated every 25 shares into 1 share and proportionally increased the per-share price.

  Item 8.01 verify on EDGAR →
• medium

  The company issued a press release on April 21, 2026, attached as an exhibit; specific content not disclosed in the 8-K body.

  Item 9.01 verify on EDGAR →